InMed Pharmaceuticals Inc.

NasdaqCM:INM Stock Report

Market Cap: US$1.5m

InMed Pharmaceuticals Management

Management criteria checks 3/4

InMed Pharmaceuticals' CEO is Eric Adams, appointed in Jun 2016, has a tenure of 7.83 years. total yearly compensation is $367.57K, comprised of 75.7% salary and 24.3% bonuses, including company stock and options. directly owns 0.73% of the company’s shares, worth $11.08K. The average tenure of the management team and the board of directors is 3.4 years and 2 years respectively.

Key information

Eric Adams

Chief executive officer

US$367.6k

Total compensation

CEO salary percentage75.7%
CEO tenure7.8yrs
CEO ownership0.7%
Management average tenure3.4yrs
Board average tenure2yrs

Recent management updates

Recent updates

InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M

Sep 26

InMed Pharma announces $6M private placement

Sep 09

InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens

Jul 25

InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement

Jul 13

InMed To Acquire Rare Cannabinoid Manufacturer BayMedica

Jul 02

InMed's INM-755 CBN cream did not introduce any delay in normal wound healing

Jan 08

CEO Compensation Analysis

How has Eric Adams's remuneration changed compared to InMed Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$6m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023US$368kUS$278k

-US$8m

Mar 31 2023n/an/a

-US$15m

Dec 31 2022n/an/a

-US$17m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022US$468kUS$363k

-US$19m

Mar 31 2022n/an/a

-US$14m

Dec 31 2021n/an/a

-US$14m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021US$735kUS$328k

-US$10m

Mar 31 2021n/an/a

-US$9m

Dec 31 2020n/an/a

-US$7m

Sep 30 2020n/an/a

-US$8m

Jun 30 2020US$424kUS$287k

-US$9m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019n/an/a

-US$11m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019US$1mUS$287k

-US$10m

Mar 31 2019n/an/a

-US$9m

Dec 31 2018n/an/a

-US$8m

Sep 30 2018n/an/a

-US$7m

Jun 30 2018US$2mUS$240k

-US$6m

Mar 31 2018n/an/a

-US$6m

Dec 31 2017n/an/a

-US$5m

Sep 30 2017n/an/a

-US$5m

Jun 30 2017US$346kUS$161k

-US$3m

Compensation vs Market: Eric's total compensation ($USD367.57K) is below average for companies of similar size in the US market ($USD668.06K).

Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.

CEO

Eric Adams (60 yo)

7.8yrs

Tenure

US$367,571

Compensation

Mr. Eric A. Adams, B.S. Chem., MIBS., has been the Chief Executive Officer and President at InMed Pharmaceuticals Inc. since June 16, 2016. Mr. Adams served as a Strategic Advisor of Augurex Life Sciences...

Leadership Team

NamePositionTenureCompensationOwnership
Eric Adams
President7.8yrsUS$367.57k0.73%
$ 11.1k
Michael Woudenberg
Chief Operating Officer1.8yrsUS$297.42k0.00035%
$ 5.3
Alexandra Mancini
Senior Vice President of Clinical & Regulatory Affairs7.5yrsUS$284.92k0.0040%
$ 60.4
Sazzad Hossain
Co-Founderno dataUS$142.43kno data
N. Jagpal
CFO & Corporate Secretaryless than a yearno datano data
Sarah Li
VP of Accounting & Controller4.3yrsno datano data
Colin Clancy
Senior Director of Investor Relationsno datano datano data
Jerry Griffin
Vice President of Sales & Marketing2.2yrsno datano data
Eric Hsu
Senior Vice President of Preclinical Research & Development6.1yrsUS$282.92k0.00084%
$ 12.8
Shane Johnson
Senior VP & GM of BayMedica2.5yrsno data0.20%
$ 3.1k
Ado Muhammad
Senior Consultant of Medical Affairsno datano datano data

3.4yrs

Average Tenure

57yo

Average Age

Experienced Management: INM's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Eric Adams
President7.8yrsUS$367.57k0.73%
$ 11.1k
Andrew Hull
Independent Chair of the Board7.6yrsUS$61.10k0.63%
$ 9.6k
Bryan Baldasare
Independent Director1.9yrsUS$48.60k0%
$ 0
Janet Grove
Independent Director2.2yrsUS$48.60k0%
$ 0
Nicole Lemerond
Independent Director1.7yrsUS$46.21k0%
$ 0
David Morgan
Member of Scientific Advisory Boardno datano datano data

2.0yrs

Average Tenure

58yo

Average Age

Experienced Board: INM's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.